ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

2015 Goal Not a Dream, But a Vision, Director Says

July 18, 2003

Tamoxifen Offers Long-Term Benefits For Prevention

March 30, 2007

Cancer Education: NCI Offers Training In Epidemiology And Genetics

April 17, 1998

Review Planned Of 54 Deaths In First 60 Days On Studies.

June 22, 2001

NIH RPG Success Rate to Fall Further

June 7, 2013

Revlimid Also Demonstrates Response in Mantle Cell

July 29, 2011